AstraZeneca and three affiliates will move 350 employees to a new site in South San Francisco’s Cove at Oyster Point. AstraZeneca, along with Acerta Pharma, MedImmune and Pearl R&D facilities, will move into the new location during Q4 2017.

“Our new South San Francisco location—where biotech and Silicon Valley intersect—brings all of our California employees to one site and provides opportunities to access existing science both inside and outside our walls,” says AstraZeneca EVP, global medicines development and chief medical officer Sean Bohen.

AstraZeneca expects cost benefits with the move, including better space utilization and energy efficiency. Other benefits include access to Caltrain, BART, ferry transportation, fitness and recreation, restaurants and shopping.

AstraZeneca affiliate ZS Pharma, based in San Francisco, which was acquired at the end of last year, was not included in the planned move, but will revisit the decision next year.

The Cove includes seven buildings with 115k SF to 182k SF. A full-service amenities center offers 30k SF, a fitness center, group exercise rooms, bowling lanes, a gaming area and a café.